Properties (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
risankizumab-rzaa
|
| gptkbp:administrativeDivision |
every 12 weeks after initial doses
|
| gptkbp:brand |
Skyrizi
|
| gptkbp:chemicalFormula |
C6420H9934N1716O1990S44
|
| gptkbp:clinicalTrials |
autoimmune diseases
Phase III Crohn's disease treatment guidelines KEEPsAKE trial SEEK trial American_Academy_of_Dermatology_guidelines MIRROR_trial |
| gptkbp:contraindication |
active infections
hypersensitivity to the drug serious infections malignancies |
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
AbbVie
|
| gptkbp:dosageForm |
pre-filled syringe
|
| gptkbp:drugInterdiction |
half-life of approximately 28 days
neutralizes IL-23 |
| gptkbp:firstAppearance |
April 2019
|
| gptkbp:formulation |
solution for injection
|
| gptkbp:hasPopulation |
adults
pediatric patients (age 6 and older) |
| https://www.w3.org/2000/01/rdf-schema#label |
risankizumab
|
| gptkbp:mandates |
moderate to severe plaque psoriasis
moderate_to_severe_Crohn's_disease |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
dermatology
immunology gastroenterology |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sideEffect |
fatigue
headache nausea injection site reactions upper respiratory infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
IL-23
|
| gptkbp:triggerType |
IL-23 inhibition
|
| gptkbp:usedFor |
treatment of psoriasis
treatment of Crohn's disease |
| gptkbp:weight |
146 kDa
|